Drug Type Small molecule drug |
Synonyms Benfotiamine/Riboflavin Butyrate/Nicotinamide/Calcium Pantothenate/Pyridoxal Phosphate Hydrate/D-Biotin/Folic Acid/Mecobalamin/Ascorbic Acid/Cholecalciferol Concentrate Powder/Selenium In Dried Yeast/Gamma-Oryzanol/Magnesium Oxide/Zinc Oxide/Ursodeoxycholic Acid/Inositol, SSenBQ ActB Tab., 쎈비큐액트비정 |
Action inhibitors, stimulants, antagonists, + [2] |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors), APP inhibitors(Beta amyloid A4 protein inhibitors), DNMT1 stimulants(DNA (cytosine-5)-methyltransferase 1 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (14 Jul 2026), |
Regulation- |
Molecular FormulaC19H23N4O6PS |
InChIKeyBTNNPSLJPBRMLZ-UHFFFAOYSA-N |
CAS Registry22457-89-2 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Avitaminosis | South Korea | 14 Jul 2026 |





